BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes

References

• Georgianos PI, Vaios V, Eleftheriadis T, et al. Therapeutic advances in diabetic kidney disease. Int J Mol Sci. 2023;24(3):2803. doi: 10.3390/ijms24032803
   PubMed Web of Science ®Google Scholar
• Mima A. A narrative review of diabetic kidney disease: previous and current evidence-based therapeutic approaches. Adv Ther. 2022;39(8):3488–3500. doi: 10.1007/s12325-022-02223-0
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi: 10.1056/NEJMoa2024816
   PubMed Web of Science ®Google Scholar
• Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–127.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/NEJMoa1811744
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229. doi: 10.1056/NEJMoa2025845
   PubMed Web of Science ®Google Scholar
• Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–2263. doi: 10.1056/NEJMoa2110956
   PubMed Web of Science ®Google Scholar
• de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Kidney Int. 2022;102(5):974–989. doi: 10.1016/j.kint.2022.08.012
   PubMed Web of Science ®Google Scholar
• Mazidi M, Rezaie P, Gao HK, et al. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017;6(6):e004007. doi: 10.1161/JAHA.116.004007
   PubMed Web of Science ®Google Scholar
• Georgianos PI, Agarwal R. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide. Diabetes Care. 2019;42(4):693–700. doi: 10.2337/dc18-2207
   PubMed Web of Science ®Google Scholar
• Wilcox CS. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors. Hypertension. 2020;75(4):894–901. doi: 10.1161/HYPERTENSIONAHA.119.11684
   PubMed Web of Science ®Google Scholar
• Herat LY, Magno AL, Rudnicka C, et al. SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection. JACC Basic Transl Sci. 2020;5(2):169–179. doi: 10.1016/j.jacbts.2019.11.007
   PubMedGoogle Scholar
• Cherney DZI, Cooper ME, Tikkanen I, et al. Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018;93(1):231–244. doi: 10.1016/j.kint.2017.06.017
   PubMed Web of Science ®Google Scholar
• Ye N, Jardine MJ, Oshima M, et al. Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial. Circulation. 2021;143(18):1735–1749. doi: 10.1161/CIRCULATIONAHA.120.048740
   PubMed Web of Science ®Google Scholar
• Georgianos PI, Agarwal R. Mineralocorticoid receptor antagonism in chronic kidney disease. Kidney Int Rep. 2021;6(9):2281–2291. doi: 10.1016/j.ekir.2021.05.027
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Agarwal R, Anker SD, et al. Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes. Hypertension. 2022;79(1):2685–2695. doi: 10.1161/HYPERTENSIONAHA.122.19744
   PubMedGoogle Scholar
• Stergiou GS, Palatini P, Parati G, et al. 2021 European society of hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39(7):1293–1302. doi: 10.1097/HJH.0000000000002843
   PubMed Web of Science ®Google Scholar
• Yang WY, Melgarejo JD, Thijs L, et al. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA. 2019;322(5):409–420. doi: 10.1001/jama.2019.9811
   PubMed Web of Science ®Google Scholar
• Agarwal R, Ruilope LM, Ruiz-Hurtado G, et al. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023;41(2):295–302. doi: 10.1097/HJH.0000000000003330
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884–894. doi: 10.1001/jama.2015.10081
   PubMed Web of Science ®Google Scholar
• Green JB, Mottl AK, Bakris G, et al. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2023;38(4):894–903. doi: 10.1093/ndt/gfac198
   PubMed Web of Science ®Google Scholar